Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
Business Wire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 net product revenue $323.8 million, including $240.3 million PMO revenue
- ➤2026 total revenue guidance raised to $1.25 billion-$1.3 billion
- ➤2026 expense guidance narrowed to $800 million-$825 million
- ➤Q3 non-GAAP operating income $22.9 million versus $35.7 million loss
- ➤SRP-1003 and SRP-1001 multiple ascending dose data expected in Q4 2026
Expert Statements
Michael Severino, Chief Executive Officer of Sarepta Therapeutics
“After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.”
Michael Severino, Chief Executive Officer of Sarepta Therapeutics
“This quarter, we saw continued strength in our commercial execution.”
Michael Severino, Chief Executive Officer of Sarepta Therapeutics
“Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve.”
Michael Severino, Chief Executive Officer of Sarepta Therapeutics
“We are already preparing both programs for potential late-stage development with the intent of moving efficiently if the results support advancement.”
Michael Severino, Chief Executive Officer of Sarepta Therapeutics
“We have work to do, and I want us to be measured by execution, but I believe Sarepta has the commercial foundation, pipeline opportunities and financial strength to deliver meaningful long-term value.”
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
* Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs
Get started
Create a free account to read the full story.